What question did this study set out to answer?

This research aims to compare the metabolic outcomes of two antiretroviral treatments in individuals new to HIV treatment.

Metabolic outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir/lamivudine in treatment-naïve people living with HIV: a 48-week retrospective study

View Full Paper

Ask AI

Bookmark

This research aims to compare the metabolic outcomes of two antiretroviral treatments in individuals new to HIV treatment.
Retrospective analysis of 499 treatment-naïve people living with HIV.
Participants initiated either bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir/lamivudine.
Follow-up period lasted for 48 weeks.
Both treatments achieved comparable metabolic outcomes at 48 weeks.
Increased body mass index (BMI) was significantly associated with bictegravir/emtricitabine/tenofovir alafenamide.

No takes yet. Share an insight, caveat, or question.

Retrospective analysis reveals similar efficacy and safety of dolutegravir/lamivudine and other treatments in treatment-naïve individuals.

Guo et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis reveals similar efficacy and safety of dolutegravir/lamivudine and other treatments in treatment-naïve individuals.